{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:22:52Z","timestamp":1740147772105,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s11899-021-00651-3","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T12:03:33Z","timestamp":1631189013000},"page":"483-489","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Management of Myelofibrosis-Associated Anemia: Focus on Standard Agents and Novel Therapeutics in Phase 3 Clinical Trials"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9713-5299","authenticated-orcid":false,"given":"Brady L.","family":"Stein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,9]]},"reference":[{"issue":"4","key":"651_CR1","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","volume":"6","author":"W Dameshek","year":"1951","unstructured":"Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6(4):372\u20135.","journal-title":"Blood"},{"key":"651_CR2","doi-asserted-by":"publisher","unstructured":"Marneth AE, Mullally A. The molecular genetics of myeloproliferative neoplasms. Cold Spring Harb Perspect Med. 2020;10(2):a034876. https:\/\/doi.org\/10.1101\/cshperspect.a034876.","DOI":"10.1101\/cshperspect.a034876"},{"issue":"1","key":"651_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","volume":"10","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, et al. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017;10(1):55.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"651_CR4","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/leu.2016.148","volume":"30","author":"CN Harrison","year":"2016","unstructured":"Harrison CN, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30(8):1701\u20137.","journal-title":"Leukemia"},{"issue":"17","key":"651_CR5","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1056\/NEJMc1502524","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(17):1670\u20131.","journal-title":"N Engl J Med"},{"issue":"5","key":"651_CR6","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","volume":"1","author":"A Pardanani","year":"2015","unstructured":"Pardanani A, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol. 2015;1(5):643\u201351.","journal-title":"JAMA Oncol"},{"issue":"7","key":"651_CR7","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","volume":"4","author":"CN Harrison","year":"2017","unstructured":"Harrison CN, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol. 2017;4(7):e317\u201324.","journal-title":"Lancet Haematol"},{"issue":"4","key":"651_CR8","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","volume":"36","author":"P Guglielmelli","year":"2018","unstructured":"Guglielmelli P, et al. MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol. 2018;36(4):310\u20138.","journal-title":"J Clin Oncol"},{"key":"651_CR9","unstructured":"Myeloproliferative neoplasms. NCCN Guidelines 2021 [cited 2021 2\/22\/21]."},{"issue":"17","key":"651_CR10","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1182\/blood-2014-07-575373","volume":"124","author":"F Cervantes","year":"2014","unstructured":"Cervantes F. How I treat myelofibrosis. Blood. 2014;124(17):2635\u201342.","journal-title":"Blood"},{"issue":"5","key":"651_CR11","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1111\/bjh.15964","volume":"186","author":"EM Elli","year":"2019","unstructured":"\u2022 Elli EM, et al. Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study). Br J Haematol. 2019;186(5):e123\u20136. The role of iron chelation is unclear in Myelofibrosis. This is a multicenter study showed that 43% had an erythroid response to iron chelation.","journal-title":"Br J Haematol"},{"issue":"4","key":"651_CR12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/ejh.12846","volume":"98","author":"JC Hernandez-Boluda","year":"2017","unstructured":"Hernandez-Boluda JC, et al. Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis. Eur J Haematol. 2017;98(4):407\u201314.","journal-title":"Eur J Haematol"},{"issue":"5","key":"651_CR13","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/bjh.15450","volume":"182","author":"E Crisa","year":"2018","unstructured":"Crisa E, et al. The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib. Br J Haematol. 2018;182(5):701\u20134.","journal-title":"Br J Haematol"},{"issue":"1","key":"651_CR14","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3109\/10428194.2015.1046866","volume":"57","author":"JC Hernandez-Boluda","year":"2016","unstructured":"Hernandez-Boluda JC, et al. Long-term results of prednisone treatment for the anemia of myelofibrosis. Leuk Lymphoma. 2016;57(1):120\u20134.","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"651_CR15","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s00277-015-2435-7","volume":"94","author":"F Cervantes","year":"2015","unstructured":"Cervantes F, et al. Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results. Ann Hematol. 2015;94(11):1791\u20136.","journal-title":"Ann Hematol"},{"key":"651_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.leukres.2017.06.005","volume":"60","author":"K Gowin","year":"2017","unstructured":"Gowin K, et al. Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis. Leuk Res. 2017;60:31\u20135.","journal-title":"Leuk Res"},{"issue":"1","key":"651_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41408-017-0029-4","volume":"8","author":"X Luo","year":"2018","unstructured":"Luo X, et al. Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response. Blood Cancer J. 2018;8(1):9.","journal-title":"Blood Cancer J"},{"issue":"4","key":"651_CR18","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/leu.2016.300","volume":"31","author":"A Tefferi","year":"2017","unstructured":"Tefferi A, et al. A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence. Leukemia. 2017;31(4):896\u2013902.","journal-title":"Leukemia"},{"issue":"1","key":"651_CR19","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/ajh.21892","volume":"86","author":"P Thapaliya","year":"2011","unstructured":"Thapaliya P, et al. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens. Am J Hematol. 2011;86(1):96\u20138.","journal-title":"Am J Hematol"},{"issue":"22","key":"651_CR20","doi-asserted-by":"publisher","first-page":"4436","DOI":"10.1182\/blood-2010-05-287417","volume":"116","author":"RA Mesa","year":"2010","unstructured":"Mesa RA, et al. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood. 2010;116(22):4436\u20138.","journal-title":"Blood"},{"issue":"12","key":"651_CR21","doi-asserted-by":"publisher","first-page":"e956","DOI":"10.1016\/j.clml.2020.07.006","volume":"20","author":"F Castillo-Tokumori","year":"2020","unstructured":"\u2022 Castillo-Tokumori F, et al. Retrospective analysis of the clinical use and benefit of lenalidomide and thalidomide in myelofibrosis. Clin Lymphoma Myeloma Leuk. 2020;20(12):e956\u201360. This is a more contemporary retrospective study demonstrating response rates for immunomodulatory drugs when used to treat MF anemia.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"18","key":"651_CR22","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1182\/bloodadvances.2020002662","volume":"4","author":"ST Oh","year":"2020","unstructured":"\u2022 Oh ST, et al. ACVR1\/JAK1\/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. Blood Adv. 2020;4(18):4282\u201391. This study provides some proof of principle regarding the ability of momelotonib to suppress hepcidin and offer anemia responses in some patients with MF and transfusion-dependent anemia.","journal-title":"Blood Adv"},{"issue":"13","key":"651_CR23","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1182\/blood-2016-09-740092","volume":"129","author":"M Asshoff","year":"2017","unstructured":"Asshoff M, et al. Momelotinib inhibits ACVR1\/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. Blood. 2017;129(13):1823\u201330.","journal-title":"Blood"},{"issue":"34","key":"651_CR24","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","volume":"35","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, et al. SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naive patients with myelofibrosis. J Clin Oncol. 2017;35(34):3844\u201350.","journal-title":"J Clin Oncol"},{"issue":"2","key":"651_CR25","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","volume":"5","author":"CN Harrison","year":"2018","unstructured":"Harrison CN, et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol. 2018;5(2):e73\u201381.","journal-title":"Lancet Haematol"},{"issue":"Supplement_1","key":"651_CR26","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1182\/blood-2019-122546","volume":"134","author":"AT Gerds","year":"2019","unstructured":"Gerds AT, et al. A phase 2 study of luspatercept in patients with myelofibrosis-associated anemia. Blood. 2019;134(Supplement_1):557\u2013557.","journal-title":"Blood"},{"issue":"Supplement_1","key":"651_CR27","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1182\/blood-2019-122546","volume":"134","author":"AT Gerds","year":"2020","unstructured":"Gerds AT, et al. Duration of response to luspatercept in patients (Pts) requiring red blood cell (RBC) transfusions with myelofibrosis (MF) - updated data from the phase 2 ACE-536-MF-001 Study. Blood. 2020;134(Supplement_1):557 ((557)).","journal-title":"Blood"},{"issue":"1","key":"651_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","volume":"33","author":"M Kleppe","year":"2018","unstructured":"Kleppe M, et al. Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms. Cancer Cell. 2018;33(1):29-43 e7.","journal-title":"Cancer Cell"},{"key":"651_CR29","unstructured":"Talpaz Mea. CPI-0610, a bromodomain and extraterminal domain protein (BET) inhibitor, as monotherapy in advanced myelofibrosis patients refractory\/intolerant to JAK inhibitor: update from phase 2 MANIFEST Study. Blood. 2020. 134(Paper 2163)."},{"key":"651_CR30","unstructured":"Verstovsek S et al. CPI-0610, bromodomain and extraterminal domain protein (BET) inhibitor, as \u201cadd-on\u201d to ruxolitinib, in advanced myelofibrosis patients with suboptimal response: update of MANIFEST Phase 2 Study. Blood. 2020(Supplement_1): p. Abstract 56."},{"key":"651_CR31","unstructured":"Mascarenhas J et al. CPI-0610, a bromodomain and extraterminal domain protein (BET) inhibitor, in combination with ruxolitinib, in JAK-inhibitor-na\u00efve myelofibrosis patients: update of MANIFEST Phase 2 Study. Blood. 2020(Supplement_1): p. Abstract 55."}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-021-00651-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-021-00651-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-021-00651-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T16:43:51Z","timestamp":1635353031000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-021-00651-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,9]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["651"],"URL":"https:\/\/doi.org\/10.1007\/s11899-021-00651-3","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"type":"print","value":"1558-8211"},{"type":"electronic","value":"1558-822X"}],"subject":[],"published":{"date-parts":[[2021,9,9]]},"assertion":[{"value":"9 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by the author.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}